Evidence map›Paper›PMID 23459007›Full record

ArticlePLoS pathogens2013

Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.

Susanne Eriksson, Erin H Graf, Viktor Dahl, Matthew C Strain, Steven A Yukl, Elena S Lysenko, Ronald J Bosch, Jun Lai, Stanley Chioma, Fatemeh Emad and 13 more

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03980665 (The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART), which is not on this map. Cited by 410 papers.

0numbers the graph read from it
0cells of the map it votes in
410citing papers in PubMed
26.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03980665 phase1unknown statusnot on this mapstarted 2019, after this paper: background citation

The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART

TypeinterventionalSponsorGuangzhou 8th People's HospitalRan2019 to 2025Enrolled20ConditionsHIV/AIDSArmsArsenic Trioxide
3 · Its place in the literature

Who cites it

410 citing papers in PubMed, 574 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. IBA-1Research square · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article

350 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 2 countries.

Susanne ErikssonDepartment of Diagnostics and Vaccinology, Swedish Institute for Communicable Diseases, Solna, Sweden.
Erin H Graf
Viktor Dahl
Matthew C Strain
Steven A Yukl
Elena S Lysenko
Ronald J Bosch
Jun Lai
Stanley Chioma
Fatemeh Emad
Mohamed Abdel-Mohsen
Rebecca Hoh
Frederick Hecht
Peter Hunt
Ma Somsouk
Joseph Wong
Rowena Johnston
Robert F Siliciano
Douglas D Richman
Una O'Doherty
Sarah Palmer
Steven G Deeks
Janet D Siliciano
University of California, San Francisco · USJohns Hopkins University · USUniversity of Pennsylvania · USJohns Hopkins Medicine · USKarolinska Institutet · SEVA San Diego Healthcare System · USAmerican Foundation for AIDS Research · USHarvard University Press · USSan Francisco VA Medical Center · USSwedish Institute · SE

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SPINA, CELSA A · 2011 to 2015
$39.5M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PALMER, SARAH ELIZABETH · 2011 to 2015
$29.5M
Transmission ProbabilityP01AI074621 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2008 to 2012
$23.1M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
Significance of Low Level Viremia in Patients on HAARTR37AI051178 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 2007 to 2016
$2.4M
CSRD VA IK2 CX000520Howard Hughes Medical InstituteNCI NIH HHS K23 CA157929NCRR NIH HHS UL 1 RR024131NIAID NIH HHS 1U19AI096109NIAID NIH HHS AI080193NIAID NIH HHS AI096113NIAID NIH HHS AI306214NIAID NIH HHS AI69432-SNIAID NIH HHS AI74621NIAID NIH HHS K24 AI069994NIAID NIH HHS P01 AI074621NIAID NIH HHS P01 AI080193NIAID NIH HHS P30 AI027763NIAID NIH HHS R24 AI106039NIAID NIH HHS R37 AI051178NIAID NIH HHS T32 AI007632NIAID NIH HHS U01 AI069432NIAID NIH HHS U19 AI096109NIAID NIH HHS U19 AI096113NIAID NIH HHS UM1 AI069432NIDDK NIH HHS P30 DK026743NIMH NIH HHS P30 MH062246NIMH NIH HHS P30 MH62246PHS HHS 43222PHS HHS K24AIO69994PHS HHS P30 AIO27763PHS HHS R01AIO87145
6 · The paper itself

Abstract

HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4(+) T cells carrying latent but replication-competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4(+) T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4(+) T cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays. The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research.

Indexed as

AdultAgedAntiretroviral Therapy, Highly ActiveCD4-Positive T-LymphocytesDisease ReservoirsDNA, ViralFemaleHIVHIV InfectionsHumansLeukocytes, MononuclearLongitudinal StudiesMaleMiddle AgedPolymerase Chain ReactionProvirusesDNA, ViralRNA, Viral

Identifiers

PMID23459007
PMCPMC3573107
OpenAlexW2011208161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.